- Home
- CRIS vs ACXP Comparison
CRIS vs ACXP Comparison
Compare CRIS & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- ACXP
- Stock Information
- Founded
- CRIS 2000
- ACXP 2017
- Country
- CRIS United States
- ACXP United States
- Employees
- CRIS N/A
- ACXP N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- ACXP Health Care
- Exchange
- CRIS Nasdaq
- ACXP Nasdaq
- Market Cap
- CRIS 22.9M
- ACXP 6.8M
- IPO Year
- CRIS 2000
- ACXP 2021
- Fundamental
- Price
- CRIS $1.76
- ACXP $4.16
- Analyst Decision
- CRIS Strong Buy
- ACXP Strong Buy
- Analyst Count
- CRIS 2
- ACXP 3
- Target Price
- CRIS $16.50
- ACXP $143.67
- AVG Volume (30 Days)
- CRIS 74.8K
- ACXP 68.2K
- Earning Date
- CRIS 11-13-2025
- ACXP 11-12-2025
- Dividend Yield
- CRIS N/A
- ACXP N/A
- EPS Growth
- CRIS N/A
- ACXP N/A
- EPS
- CRIS N/A
- ACXP N/A
- Revenue
- CRIS $11,405,000.00
- ACXP N/A
- Revenue This Year
- CRIS $1.41
- ACXP N/A
- Revenue Next Year
- CRIS $7.46
- ACXP N/A
- P/E Ratio
- CRIS N/A
- ACXP N/A
- Revenue Growth
- CRIS 12.24
- ACXP N/A
- 52 Week Low
- CRIS $1.02
- ACXP $3.80
- 52 Week High
- CRIS $6.44
- ACXP $44.00
- Technical
- Relative Strength Index (RSI)
- CRIS 53.47
- ACXP 37.17
- Support Level
- CRIS $1.63
- ACXP $4.09
- Resistance Level
- CRIS $1.95
- ACXP $4.34
- Average True Range (ATR)
- CRIS 0.12
- ACXP 0.44
- MACD
- CRIS -0.08
- ACXP 0.10
- Stochastic Oscillator
- CRIS 90.26
- ACXP 9.94
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.